COMMUNIQUÉS West-GlobeNewswire

Eve & Co Announces Third German Supply Agreement for Immediate Release
06/09/2019
TORONTO, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (the “Company” or “Eve & Co”) (TSXV: EVE; OTCQB: EEVVF) is pleased to announce that its wholly-owned subsidiary Natural MedCo Ltd. has entered [...]
Organogenesis Announces Annual College Scholarship Award Winner
06/09/2019
Baylah Mazonson, 2019 Regenerative Medicine Scholarship Recipient, Will Attend Boston University This Fall CANTON, Mass., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading [...]
Capricor Therapeutics to Present at Upcoming Conferences
06/09/2019
LOS ANGELES, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of [...]
BIOLIFE4D Launches Second Regulation A+ (Mini-IPO) Offering Due to Popular Demand
06/09/2019
Company surpassed $2M in accepted investments during highly successful first equity crowdfunding event; expects to make significant scientific announcement in the near future CHICAGO, Sept. 06, 2019 (GLOBE NEWSWIRE) -- [...]
Agile Therapeutics to Present at Upcoming Investor Conferences
06/09/2019
PRINCETON, N.J., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari, will present at two [...]
BeyondSpring to Present at the H.C. Wainwright 21st Annual Global Investment Conference
06/09/2019
NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced [...]
Nabriva Therapeutics Earns $5 Million Milestone Payment under its License Agreement with Sinovant Sciences
06/09/2019
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti- [...]
Novavax to Present at the H.C. Wainwright 21st Annual Global Investment Conference
06/09/2019
GAITHERSBURG, Md., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C [...]
Algernon Announces Pricing of Prospectus Offering
06/09/2019
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (“ Algernon ” or “ Company [...]
Opthea Presents Positive Data from OPT-302 Phase 2b Wet AMD Trial at EURETINA Congress
06/09/2019
MELBOURNE, Australia, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical biopharmaceutical company developing novel biologic therapies for eye diseases, announced today that new clinical data from [...]
Myovant Sciences’ Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance
06/09/2019
Roivant’s ownership interest in Myovant Sciences (approximately 46% of shares issued and outstanding) to be fully assumed by a new entity, Sumitomo Dainippon-Roivant Alliance, which will be wholly owned by Sumitomo [...]
BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress
06/09/2019
NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases [...]
European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
06/09/2019
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stage small cell lung [...]
European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer
06/09/2019
The approval of the new Tecentriq-based combination expands treatment options for people across Europe affected by non-squamous non-small cell lung cancer (NSCLC) Decision based on data showing that the Tecentriq plus [...]
SunGen Pharma Receives Seventh ANDA Approval from US FDA
06/09/2019
PRINCETON, N.J., Sept. 05, 2019 (GLOBE NEWSWIRE) -- SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products, today announced it [...]
Turning Point Therapeutics Announces Pricing of Public Offering of Common Stock
06/09/2019
SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the pricing of its [...]
Ascent Industries Provides Bi-Weekly Default Status Report
06/09/2019
VANCOUVER, British Columbia, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Ascent Industries Corp. ( CSE: ASNT ) (“ Ascent ” or the “ Company ”) is providing this bi-weekly default status report in accordance with National Policy [...]
Zealand Pharma major shareholder announcement: Van Herk Investments
05/09/2019
Company announcement – No. 31 / 2019 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, September 5, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen- [...]
President & CEO of Nova Leap Health Corp. to Present at the 12th Annual LD Micro Main Event
05/09/2019
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Sept. 05, 2019 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a 2019 [...]

Pages